<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04845659</url>
  </required_header>
  <id_info>
    <org_study_id>AIPAC21</org_study_id>
    <nct_id>NCT04845659</nct_id>
  </id_info>
  <brief_title>Avatrombopaq In Patients With Cirrhosis</brief_title>
  <acronym>AIPAC</acronym>
  <official_title>Treatment With Avatrombopaq in Patients With Cirrhosis Undergoing Small Invasive Procedure: A Prospective Case Series</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thrombocytopenia is a frequent issue in patients with cirrhosis undergoing various types of&#xD;
      procedures (e.g. liver biopsy, endoscopy and minor surgical interventions). Thrombocytopenia&#xD;
      &lt; 50*10^9/L increases the risk of perioperative and postoperative bleedning and might prevent&#xD;
      patients with cirrhosis to undergo important procedures. Doptelet is a small molecular&#xD;
      trombopoetin agonist, which results in proliferation and differentiation of megakaryocytes in&#xD;
      the bone marrow resulting in increased levels of thrombocytes. It is given orally as a pill&#xD;
      and is used to increase platelet count in patients with severe thrombocytopenia (&lt; 50*10^9/L)&#xD;
      and cirrhosis and thus not to normalize platelet count. This study investigates the safety&#xD;
      and efficacy of Doptelet in patients with cirrhosis and thrombocytopenia (&lt; 50*10^9/L)&#xD;
      undergoing minor procedures like Transjugular Adjusted Liver Biopsy (TJALB) and gastroscopy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>3 months postprocedural</time_frame>
    <description>Mortality, bleedning, blood clots, readmission, reoperation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Thrombocytopenia; Drugs</condition>
  <condition>Cirrhosis, Liver</condition>
  <condition>Procedural Bleeding</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avatrombopaq administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doptelet Pill</intervention_name>
    <description>40 mg or 60 mg Doptelet orally 10-13 days before planned procedure.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: &gt;17 years and ≤80 years&#xD;
&#xD;
          -  ASA I-III&#xD;
&#xD;
          -  Patients who read, understood and signed informed consent.&#xD;
&#xD;
          -  Patients with a diagnosis of cirrhosis&#xD;
&#xD;
          -  Thrombocytopenia &lt;50*109&#xD;
&#xD;
          -  The patient is scheduled for one of the following procedures: Transjugular Adjusted&#xD;
             Liver Biopsy (TJALB), gastroscopy or percutan paracentesis of ascites in the following&#xD;
             month.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who do not speak and understand Danish.&#xD;
&#xD;
          -  Patients who cannot cooperate within the trial.&#xD;
&#xD;
          -  Patients who did not sign an informed consent regardless of the cause.&#xD;
&#xD;
          -  Active drug abuse - to the discretion of the investigator.&#xD;
&#xD;
          -  Thrombocytes &gt;50*10^9&#xD;
&#xD;
          -  Patients with hereditary trombolic diseases (e.g. Factor V Leiden, antithrombin&#xD;
             deficiency, protein S and C deficiency, prothrombin G202110A mutation).&#xD;
&#xD;
          -  INR &gt; 1,7&#xD;
&#xD;
          -  Ongoing infection verified by blood culture, clinical examination, and acute phase&#xD;
             reactants (e.g. CRP)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christian Snitkjær, M.B.</last_name>
    <phone>+4523670279</phone>
    <email>christian_snit@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Line Molzen, M.D.</last_name>
    <email>line.molzen.02@regionh.dk</email>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 11, 2021</study_first_submitted>
  <study_first_submitted_qc>April 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>April 11, 2021</last_update_submitted>
  <last_update_submitted_qc>April 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Christian Snitkjær</investigator_full_name>
    <investigator_title>M.B.</investigator_title>
  </responsible_party>
  <keyword>Cirrhosis</keyword>
  <keyword>Thrombocytopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

